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Abstract Presented is a retrospective outcome study of a
15-year single institutional experience with a contemporary
cohort of patients with hypoplastic left heart syndrome and
complex that underwent a ‘‘Giessen Hybrid’’ stage I as initial
palliation. Hybrid approach consisting of surgical bilateral
pulmonary artery banding and percutaneous duct stenting
with or without atrial septum manipulation was developed
from a rescue approach to a first-line procedure. Compre-
hensive Aristotle score defined pre-operative condition.
Fifteen-year follow-up mortality is reported as occurring
within the staged univentricular palliation or before and after
biventricular repair. Hybrid stage I was performed in 154
patients; 107 should be treated by single ventricle palliation,
33 by biventricular repair (BVR), 7 received heart trans-
plantation, and 7 were treated by comfort care, respectively.
Overall 34 children died. The Aristotle score (mean value
18.2 ± 3) classified for univentricular circulations in new-
borns did not have statistical impact on the outcome. Two
patients died during stage I (1.2 %), and the interstage I
mortality was 6.7 %, and stage II mortality 9 %, respec-
tively. Stage III was up to now performed in 57 patients
without mortality. At 1 year, the overall unadjusted survival
of HLHS and variants was 84 % and following BVR 89 %,
respectively. The Fifteen-year survival rate for HLHS and
variants was 77 %, with no significant impact of birth weight
of less than 2.5 kg. In conclusion, Hybrid stage I fulfilled the
criteria of life-saving approach. In our institution, Hybrid
procedure replaced Norwood-staged palliation with a con-
siderable mid- and long-term survival rate. Considering
interstage mortality close surveillance is mandatory.
Keywords Hypoplastic left heart syndrome  Hypoplastic
left heart complex  Hybrid approach
Introduction
Hybrid approach expands the surgical options for patients
born with hypoplastic left heart syndrome (HLHS) and
newborns with multiple left heart obstructions, summarized
as hypoplastic left heart complex (HLHC) [18]. Despite
significant progress, surgical outcome for high-risk patients
with HLHS remains suboptimal [3, 8, 11, 17, 20, 22, 25].
The hybrid palliation lessens the initial operative risk [1] and
is hypothesized to improve in particular neurological sur-
vival [16]; however, the outcome of this sequential approach
is unknown. Improved operative outcomes have resulted in
the increasing use of the surgical palliation in high-risk
patients, but at the expense of considerable morbidity and
mortality [5, 6]. The early success with the hybrid approach
reported by Akintuerk et al. [1, 2] and Galantowicz et al. [9,
10] have prompted the increasing use of this strategy in
order to minimize the deleterious impact of the conventional
surgical intervention on high-risk patients [4, 8, 14, 26].
Moreover, aggravating factors as low birth weight and sur-
gical complexity on survival supported the idea that a less
extensive neonatal procedure could improve the outcome in
these patients [11, 22]. Therefore, we present the overall
single institutional 15-year experience with an unselected
cohort of HLHS and HLHC patients who underwent a
Hybrid procedure as initial palliation providing their mid-
and long-term outcome.
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Patients and Methods
This is a longitudinal review of all patients with HLHS, or
it’s variants as well as HLHC were admitted between June
1998 and June 2013 to the Pediatric Heart Center of the
University Hospital Giessen, in whom a Hybrid stage I
approach was performed. Patient characteristics and car-
diac anatomy are illustrated in Tables 1 and 2. The patients
are grouped according their neonatal appraisal to undergo
univentricular palliation (HLHS-group A) and biventricular
repair (HLHC-group B). In short, the definition of HLHC
in this study involves following criteria: borderline/
obstructive left heart structures, duct-dependent circulation
of the lower body, and antegrade flow to the ascending
aorta. The only exception to this definition is the diagnosis
of aortic atresia with the presence of ventricular septal
defect and two ventricles. A small group of patients (group
C) received Hybrid stage I procedure for primary listing to
orthotopic heart transplantation (HTX) or comfort care
after hybrid stage I.
Retrospective data collection included variables at
admission, operative and postoperative parameters, as well
as follow-up information during a 15-year observational
period. Risk adjustment was calculated for each patient of the
HLHS and variants group A via comprehensive Aristotle
score. However, considering that Aristotle comprehensive
score is used to classify HLHS in context of a Norwood stage
I procedure with a basis score of 14,5 and to adjust for the
complexity of the individual patient by taking into account
patient specific ‘‘procedure-independent’’ characteristics
[15]; there is currently no value assigned for the Hybrid
procedure. However, we calculated for each patient of the
HLHS and variants group A via the comprehensive Aristotle
score in order to adjust the complexity according to specific
patient and procedural characteristics prior to initial hybrid
stage I palliation, as a Norwood procedure would have be
performed as the usual standard approach.
Risk factors examined for their potential influence on
procedure-related mortality included body weight at sur-
gery, morphology of HLHS and variants, presence of aortic
atresia, additional cardiac anomalies, and comprehensive
Aristotle score. Demographic data including surgical pro-
cedures of the patients primarily classified as HLHC are
summarized in Table 2. The time and mode of corrective
surgery as well as the follow-up survival was analyzed.
Operative mortality of all surgical procedures was defined
as mortality within 30 days or prior to hospital discharge.
Additional end-points that have been investigated were
[18] hospital survival after initial Hybrid stage I palliation,
interstage I mortality, survival after stage II procedure,
interstage II mortality, and follow-up after total cavo-pul-
monary connection (stage III, completion of the Fontan
circulation). The local institutional ethics review board
approved the study, and the need for parental consent was
waived. The anatomic diagnosis of HLHS and HLHC was
based on two-dimensional echocardiography in all patients,
and in addition on magnetic resonance imaging since 2008.
Technical aspects of the initial hybrid (off-pump) palliation
Table 1 Patient demographics of HLHS and Variants
Demographic Data Value (n = 121)
Male sex, n (%) 80 (66.1 %)
Low Birth Weight (\2.5 kg) 18 (14.8 %)
Genetic abnormality 9 (7.4 %)
Primary cardiac anatomy
HLHS subtype
MA, AA 34 (28.1 %)
MS, AA 33 (27.3 %)
MA, AS 6 (5 %)
MS, AS 28 (23.1 %)










TGA ? IAA 1
DILV ? TGA ? IAA (hAOA) ?MS 4
Other 3
Table 2 Patient demographics of HLHC
Demographic Data Value (n = 33)
Male sex, n (%) 17 (52 %)
Low Birth Weight (\2.5 kg) 10 (30 %)
Genetic abnormality 10 (30 %)
Main primary cardiac anatomy
IAA ? VSD ? hypoplastic AAO 9 (27 %)
Syndromale 7
DORV ? dTGA ? hypoplastic AAO 1
Shone—complex 7
Aortic stenosis ? hypoplastic AAO 7
Others with HLHC 9
Main primary cardiac anatomy
Miscellaneous intra-cardiac repairs 25
Norwood-Rastelli/Yasui-operation 4
Rastelli-operation 3
Ross-Konno ? AOA-reconstruction 1
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have been reported previously [18, 23]. In terms of modi-
fications of the circulation, hybrid approach consists of
bilateral pulmonary banding (bPAB), percutaneous duct
stenting, or individual cases long-term prostaglandin infu-
sion. If required, atrioseptostomy optionally with stent
placement was performed. These interventions ensure
protection of the lungs from pulmonary hypertension,
preservation of an adequate systemic perfusion, and
unloading of the left atrium, respectively. Briefly, in elec-
tive patients, the hybrid stage I procedure is performed via
median sternotomy for branch pulmonary artery banding
using 3-mm (bodyweight less than 2.5 kg) or 3.5-mm
Gore-Tex (W.L. Gore, Newark, DE) rings [4]. Stenting of
the ductus arteriosus was performed in all patients by
percutaneous transcatheter approach via femoral vein or by
4F arterial access since the redesigned self-expandable
stent (Sinus-superflex-DS) has been available [23]. Heart
catheterization for duct stenting and atrial septum manip-
ulation was performed in sedated patients breathing spon-
taneously, routinely after surgical bPAB. In rescue
situations, surgical bPAB was performed in case of a pul-
monary run-off caused by a huge interatrial defect, duct
stenting to reopen a duct insensitive to prostaglandin-E1,
and atrial septal or pulmonary vein manipulation to solve
life-threatening pulmonary vein obstruction [21, 23, 24].
Stent size and positioning within the duct was based on a
right lateral oblique 30 and 90 lateral view angiography,
which were performed by a 4F Judkins or 4F multipurpose
catheter positioned either in the pulmonary trunk and/or
descending aorta, by hand injection (Fig. 1). Initially, dif-
ferent types of balloon-expandable stents were used. Since
2006, nearly exclusively self-expandable Sinus-Repo 5F
and currently Sinus-Superflex-DS stents deliverable
through a 4 F sheath with different widths of 7,8,9 and
10 mm and lengths (12, 15, 18, 20 mm) with the CE-mark
for duct stenting in newborns (OptiMed Inc. Karlsruhe,
Germany) were used. Choice of the stent was largely
influenced by the ductal anatomy and the morphology of
the ductal-aortic junction. In a subgroup of patients with
narrowed aortic isthmus or aortic coarctation, additional
short stents (5x9 mm) were placed within the isthmus;
currently the Sinus-repo self-expandable stent even with
CE-mark for pediatric CoA-stenting is available. There-
fore, flow acceleration or narrowing of the color Doppler
jet indicating obstructive retrograde coronary flow was not
per se considered as a contraindication for a hybrid
approach in patients with aortic atresia. The adequacy of a
defined atrial septal communication was determined by
echocardiographic and in some by invasive hemodynamic
measurements. If the atrial septal communication was
found to be restrictive, a balloon atrial septostomy or
deployment of an atrial septal stent was performed (Fig. 1);
in patients, intact atrial septum re-opening was achieved by
Brockenbrough technique or by application of high-fre-
quency perforation. In two patients, total anomalous
venous return was re-connected to the left atrium by
catheter technique [24]. For the last 5 years, the patients
were discharged home on medication with bisoprolol and
lisinopril in a dosage of 1 9 0.1-(0.2) mg/kg, respectively;
digoxin, furosemide, and aspirin are routinely avoided. The
standard protocol for outpatient follow-up during the
interstage I includes clinical visits in 1-2-week intervals.
Patients in the univentricular HLHSgroup were not referred
for elective complete invasive hemodynamic and angio-
graphic evaluation prior to hybrid stage II, unless a
hemodynamic issue was suspected. However, hemody-
namic assessment was performed routinely before com-
pletion of the Fontan-circulation. Since 2002, as hybrid
stage II was first time described by Akintu¨rk et al. [1],
several modifications were introduced and adapted mostly
based on the patient’s individual anatomy. In case of an
innominate subclavian artery, the segment of it’s arterial
wall was included in the aortic arch reconstruction [27].
Aortic arch reconstruction without circulatory arrest has
become routine and even the entire comprehensive stage II
procedure without cardiac arrest has been possible in sev-
eral patients [28]. The stage II surgical reconstruction
Fig. 1 Depicted is a cine picture in right anterior oblique (30) view
with a Sinus-Superflex-DS stent (8 9 18 mm) in the duct, Sinus-
Repo-DS stent (5 9 9 mm) within the coarctation, and a Sinus-
Superflex-DS (8 9 15 mm) positioned in the atrial septum. A
multipurpose 4Fr catheter is still placed in the descending aorta, a
coronary 0.014 inch guide-wire advanced through the stent in the
coarctation
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consisted of amalgamation of the proximal ascending aorta
with the main pulmonary artery, removal or resection of
the stented ductus, aortic arch reconstruction, atrial sep-
tectomy (removal of atrial septal stent), removal of the
branch pulmonary artery bands with routine angioplasty or
left pulmonary artery stenting, and bidirectional cavo-pul-
monary connection. Left bidirectional Glenn was per-
formed if a left SVC without a bridging vein was present.
Considering a Fontan-circulation, a total cavo-pulmonary
connection was performed as a stage III by utilizing an
extra-cardiac conduit in all but two patients and in the
majority with surgical fenestration (n = 40). Transcatheter
technique [19] was also used for re-opening or for creation
of a new fenestration, if necessary (n = 16). Fenestrations
were closed in some during the follow-up. The variants of
biventricular repair were described previously [2, 18]. The
detailed analysis of all patients, who received a biventric-
ular repair after initial ‘‘Giessen Hybrid approach’’ for
hypoplastic left heart variants were presented at the AATS
2014, the entire data set is submitted for publication [29].
The surgical technique of HTX with the special aspects
of the morphology in patients with HLHS was already
reported [7, 13].
Statistical Analysis
Data are presented as medians (ranges) or means (±standard
deviation) and as absolute counts with percentages where
appropriate. Continuous variables were compared using a
Mann–Whitney test and Student’s t test. Kaplan–Meier sur-
vival curves using single and cumulative end-points for death
were stratified by type of initial palliation. Analyses of risk
factors for mortality at different time points for the entire cohort
and subgroups, as well as logistic regression were performed.
Results
In this longitudinal review the end-point for outcome after
initial hybrid approach was analyzed over a time period of
15-years. The analyzed cohort consisted of 154 (57 female)
patients (121 HLHS? variants, 33 HLHC) born with mean
body weight of 3.1 ± 0.8 kg; 28 neonates had a weight less
than 2.5 kg (minimum 1.21 kg), of those fifteen were cat-
egorized to univentricular group A (n = 107). The follow-
up after Hybrid stage I procedure was complete for all of
120 surviving patients with a median of 5.3 (0.3–15) years.
Figure 2a–c summarize the results for each procedural
step, with focus on the results of staged palliative approach.
In consent with the parents, seven patients were not further
treated despite a successful hybrid stage I approach
because of chromosomal anomalies or other severe
comorbidities. One of them with a complex HLHS variant
is still alive at the age of 7 years, only palliated by hybrid
stage I. From the remaining 147 patients, seven newborns
were primarily listed for HTX and for six of them a donor
heart was available; two patients died after HTX. The
actual survival of all (n = 154) unselected patients treated
with hybrid stage I was 80, 78, and 77 % after one-, two-,
and fifteen-year, respectively. Birth weight less than
2,500 g did not have an impact on mortality (Fig. 3).
Hybrid Stage I and Interstage I
Surgical bilateral PAB was performed at a median age of 7
(range 0–237) days and duct stenting in 151 patients at 10
(2–313) days, respectively. In three patients, ductal patency
was achieved by continuous prostaglandin infusion, but in
one, secondary duct stenting was performed 6 weeks later.
During the initial hybrid procedure, sixteen (11 %) new-
borns received 2 stents. In 31 patients, manipulation of the
interatrial septum (Rashkind) was necessary, either thera-
peutically in restrictive ASDs or prophylactically espe-
cially in a thicker interatrial septum when a compromise of
the left atrial drainage could be foreseen. A stent was
placed in the atrial septum at the time of stage I in two
patients. In 6 patients, a stent was positioned in the aortic
isthmus. During the interstage I, repeated duct stenting was
necessary in 17 patients, interatrial stenting in 12 patients
and isthmus stenting in 4 infants, respectively. No proce-
dural mortality was registered, but five patients did not
recover from heart failure despite technically uneventful
hybrid approach. Two of them were successfully heart
transplanted, and three listed for HTX. Four interstage
deaths occurred suddenly at home, in three of them asso-
ciated with far distance interstage observation. Hospital
mortality following initial Hybrid stage I palliation was
1.3 % for the entire cohort. Considering patients with
HLHS and variants calculated mortality was 1.8 %. The
two hospital deaths, one during surgical pulmonary band-
ing and another one during duct stenting, were already
reported previously [18]. However, since 2001, none of the
following 134 consecutive patients died during hybrid
stage I approach. The modified comprehensive Aristotle
score of group A was 18.3 ± 3.0 (mean). Aortic atresia
was present in 68 of 121 (56 %) patients, respectively. The
end-point analysis concerning cumulative mortality along
the sequential steps of the hybrid approach including Stage
II and III palliation, presence of Aristotle score of 19 or
higher (p = 0.267), birth weight less than 2.5 kg
(p = 0.474), and aortic atresia (p = 0.943) was not asso-
ciated with lower survival (Fig. 4a–c). The overall 15-year
actuarial survival for patients with AA was 77 %. Inter-
stage I mortality for group A was 6.7 % (Fig. 2b); none of
group B died after hybrid stage I, from group C, one out of
seven died on the waiting list for HTX. Additionally, two
368 Pediatr Cardiol (2015) 36:365–373
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patients were listed during the interstage I and underwent
HTX successfully.
Follow-Up Data
From the non-transplanted 96 interstage I survivors, seven
could be switched for biventricular repair, and all of them
survived the operation. However, two of them developed a
severe post-capillary pulmonary hypertension. One was
successfully heart transplanted; the other was referred to
Boston for resection of endocardial fibroelastosis with
consecutive BVR. However, the latter patient needed
finally to be reconverted to a successful TCPC. Biven-
tricular repair was performed in 33 postnatally selected
neonates and in 7 patients during follow-up by a cross-over
from group A to B, respectively. Median age at BVR was
203 (52–417) days (Table 2). The actuarial survival rate of
biventricular repair was 89 %; there were two surgical
deaths, and two additional sudden deaths occurred in third
and fourth months after BVR at home. Chromosomal or a
syndromale disease (n = 10) did not influence the BVR
mortality. The hospital mortality for comprehensive stage
II was 9 % (8 of 89, Fig. 2c); in two of them alternative
HTX listing was refused by the parents for religious rea-
sons. ECMO service after comprehensive stage II was
necessary in five patients, two of them survived. Following
stage II, left pulmonary artery stenting was necessary in
38 % (34 of 89) patients without influencing the mortality
(p = 0.304; Fig. 5). After interstage II, before completion
of the Fontan circulation, three additional patients were
successfully heart transplanted; two further patients died
and one already listed for HTX. Therefore, transplant-free
survival of comprehensive stage II was 85,4 %. Up to now,
fifty-seven patients received stage III completion (53 %)
Fig. 2 a, b, c shows the flow chart of all patients treated by Hybrid approach. BVR biventricular repair, HLHC hypoplastic left heart complex,
HLHS hypoplastic left heart syndrome, HTX heart transplantation
Fig. 3 Kaplan–Meier acturial survival curve of all (n = 154) patients
treated by hybrid approach, differentiated by birth weight less than
2.5 kg
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and twenty patients (18.6 %) are still waiting for stage III
and seven of 107 patients (6.5 %) could be converted into
group B. The actuarial survival of all patients of group A
after one-, five-, and fifteen years was 84, 82, and 77 %,
respectively.
Discussion
The 15-year single center experience with the hybrid stage
I was focused on the outcome of all stages of univentricular
palliation and corrective biventricular surgery, respec-
tively. Considering our local setting, the hybrid stage I
approach fulfilled all attributes of a highly effective ther-
apeutic tool to treat neonates with duct-dependent systemic
blood flow even in patients with a high Aristotle score.
Therefore, the retrospective analysis was not intended to
compare the ‘‘Giessen-Hybrid’’ with classical Norwood or
Sano palliation or differently performed Hybrid proce-
dures. However, 15 years ago, our institutional outcome
with the classical Norwood procedure was comparable with
outcome data reported by Ashburn et al. [3] in the year of
2003. They reported that only 28 % of neonates undergo-
ing classical Norwood procedure reached a stage III-Fontan
completion. Based on our institutional results with the
classical Norwood procedure at this point in time and the
already published ‘‘Hybrid’’ idea from Gibbs et al. [12], in
June 1998, the Hybrid stage I program in Giessen was
started. The first patient, who is still living in a good
clinical condition, was referred as a newborn in an acute
cardiovascular failure because of a postnatal pulmonary
run-off. High urgency bPAB saved his life. After clinical
stabilization, the duct was stented by a technique, which
had been already established to palliate neonates selected
for HTX [13]. He was also the first worldwide, who
received a successful comprehensive stage II, followed by
Fontan completion. Our initial hybrid series was published
in 2002 [1]. Based on the promising initial experiences, the
hybrid approach developed to our first choice procedure for
all newborns with HLHS and variants. Since 2001, bPAB
and percutaneous duct stenting were also used for a small
group of newborns with HLHC with the goal to avoid
Fig. 4 Kaplan–Meier acturial survival curve: a HLH-LS(MA/AA/
MS/AA, MA/AS, MS/AS ? variants): candidates for Norwood I
Giessen experience June 1998–June 2013. b All patients of group A
differentiated by birth weight less than 2.5 kg. c Patients of group A
(n = 107), differentiated in term of aortic atresia (AA, n = 58) and
stenosis (AS, n = 49). AA aortic atresia, AS aortic stenosis, MA mitral
atresia, MS mitral stenosis
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neonatal Norwood procedure or to delay a high-risk sur-
gical approach together with expanding surgical options in
later infancy without compromising the survival of neo-
natal patients but still keeping the option for a uni-or
biventricular circulation [18]. A demanding controversy,
however, exists in the management of this subset of
patients with borderline small left heart, e.g. HLHC. In our
institution lastly, the decision for hybrid versus ‘‘tradi-
tional’’ surgical approach was performed on our surgeon’s
risk adjustment [29]. The criteria for cross-over from
postnatal univentricular to two ventricle approach
6–8 months later is based on the inflow and outflow
characteristics of the grown-up left ventricle obtained by
echocardiographic and additional magnetic resonance
imaging data. However, the results of BVR remains in
some patients questionable, as has been demonstrated in
these two patients, in whom the diastolic dysfunction of the
left ventricle resulted in unacceptable pulmonary hyper-
tension with consecutive need for HTX and single ventricle
re-palliation, respectively. The detailed analysis of all,
lastly biventricular-repaired patients and its further dis-
cussion are presented elsewhere [29].
The first larger series of Hybrid transcatheter-surgical
palliation as a basis for univentricular or biventricular repair
was published in 2007 [2]. Until now risk factors as low
birth weight, high Aristotle score or aortic atresia did not
statistically influence the15-year outcome data. Procedural
mortality by the ‘‘Giessen Hybrid’’ stage I approach
remained rare. Following the first and until now unique
surgical death during hybrid stage I approach, we encounter
that meticulous surgery and minimized circulatory com-
promise by anesthesiological efforts play a key role for
successful Hybrid stage I. Therefore, duct stenting and atrial
septum manipulations including stenting were performed in
the vast majority of patients extubated, only sedated and
breathing spontaneously. Innovative self-expandable stents
CE-certified for duct and coarctation stenting in neonates
with HLHS further optimized the interventional approach
[18, 23]. Considering the morphologic variability of the
ductal-aortic junction, the high incidence for atrial septum
manipulation as well as the occasional presence of an aortic
coarctation, we favor the percutaneous approach after sur-
gical bPAB. Meanwhile, the term ‘‘Hybrid approach’’ is
used for diverse procedures [9, 10, 14, 26]. Therefore, our
outcome analysis should not be generalized to other
described hybrid methods. The data of the Pediatric Heart
Network report [20] showed a one-year transplant-free sur-
vival of 64 versus 74 % for the Norwood and Sano cohorts,
respectively. The rate of serious adverse events was up to
46 %, representing a significant morbidity. Initial hybrid
treatment, including patients with a high Aristotle score is
highly effective in case of prostaglandin resistant duct
obstruction, pulmonary run off, or restrictive/intact atrial
septum [21, 23, 24]. In addition, the Hybrid stage I approach
allows postnatal resuscitation even with the option of later
compassionate therapy based on the parent’s decision-
making. However, the therapeutic objective is to achieve a
long-term prospect for patients, which is worth living after
staged procedures finalized by Fontan completion or after
biventricular repair. The Achilles’ heel of the hybrid
approach was the interstage I period, the fate of the left
pulmonary artery after comprehensive stage II, and the
diastolic dysfunction in two patients directed from univen-
tricular strategy to BVR. Based on the growing body of
literature, that the brain of newborns with HLHS develops
with some delay, thereby being more vulnerable to injury
from open-heart surgery [16], the authors are convinced, that
in principle the hybrid approach allows for a normal neu-
rological outcome, and can stand the comparison with the
Norwood palliation. Currently, a prospective study consid-
ering this topic is ongoing, and the results of the first almost
twenty analyzed patients are promising. However, without
considering the Aristotle score at admission, normal somatic
and neurological outcome can only be achieved, if there is
no negative impact of the surgical-interventional strategy per
se. The interstage deaths and also the need for HTX between
the initial procedures and even after comprehensive stage II
demonstrate these vulnerable periods. The observation of
late, post stage II deaths in two , and the need for HTX in
additional three patients demonstrate even more that not all
surviving patients have the chance for transplant-free out-
come. The same is true after Fontan completion and even in
patients after BVR. Although the presented data are
reporting about 15-year experience with the hybrid
approach, the median observation period is still to short to
reach a conclusion, which neonates really benefit from the
hybrid procedure in terms of the long-term outcome.
Fig. 5 Kaplan–Meier acturial survival curve: Patients of group A
(n = 107), differentiated in term of left pulmonary artery stenting
(LPA, n = 38) and stenosis (AS, n = 49)
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Study Limitations
The retrospective design of this study precluded the
assessment of risk factors not entered in the model. Com-
plete data of known risk factors for mortality, such as
prenatal diagnosis, were not available for many patients
and were not included in the analysis. We also identified a
high level of correlation between some of the variables,
which may have confounded the multivariable analysis and
prevented us from identifying independent associations
between variables and the outcome measures. Finally, the
duration of follow-up is currently limited to a median of
5.3 years.
Conclusion
It remains to be seen whether these encouraging results are
reflected in improved longer-term outcome for these
patients. The ongoing prospective neurological follow-up
data collection will tell us if this strategy might have
additional beneficial aspects for most patients born with
HLHS.
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